- Home
- PULM vs MBRX Comparison
PULM vs MBRX Comparison
Compare PULM & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- MBRX
- Stock Information
- Founded
- PULM 2003
- MBRX 2015
- Country
- PULM United States
- MBRX United States
- Employees
- PULM N/A
- MBRX N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- MBRX Health Care
- Exchange
- PULM Nasdaq
- MBRX Nasdaq
- Market Cap
- PULM 20.5M
- MBRX 17.1M
- IPO Year
- PULM N/A
- MBRX 2016
- Fundamental
- Price
- PULM $4.87
- MBRX $0.38
- Analyst Decision
- PULM
- MBRX Strong Buy
- Analyst Count
- PULM 0
- MBRX 4
- Target Price
- PULM N/A
- MBRX $5.00
- AVG Volume (30 Days)
- PULM 11.0K
- MBRX 4.0M
- Earning Date
- PULM 08-06-2025
- MBRX 08-12-2025
- Dividend Yield
- PULM N/A
- MBRX N/A
- EPS Growth
- PULM N/A
- MBRX N/A
- EPS
- PULM N/A
- MBRX N/A
- Revenue
- PULM $369,000.00
- MBRX N/A
- Revenue This Year
- PULM N/A
- MBRX N/A
- Revenue Next Year
- PULM $134.88
- MBRX N/A
- P/E Ratio
- PULM N/A
- MBRX N/A
- Revenue Growth
- PULM N/A
- MBRX N/A
- 52 Week Low
- PULM $1.78
- MBRX $0.25
- 52 Week High
- PULM $10.40
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- PULM 44.33
- MBRX 32.94
- Support Level
- PULM $4.65
- MBRX $0.35
- Resistance Level
- PULM $5.00
- MBRX $0.62
- Average True Range (ATR)
- PULM 0.16
- MBRX 0.05
- MACD
- PULM 0.06
- MBRX -0.02
- Stochastic Oscillator
- PULM 76.92
- MBRX 8.19
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.